These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38294999)

  • 1. Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction-associated steatotic liver disease.
    Nakano M; Kawaguchi M; Kawaguchi T; Yoshiji H
    Hepatol Res; 2024 Jul; 54(7):655-666. PubMed ID: 38294999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.
    Ma N; Bansal M; Chu J; Branch AD
    J Pediatr Gastroenterol Nutr; 2024 Aug; 79(2):229-237. PubMed ID: 38693784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT.
    Lee J; Byrne CJ; Brennan PN; MacPherson I; Dow E; Dillon JF
    Ann Hepatol; 2024; 29(2):101280. PubMed ID: 38219950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiles of advanced hepatic fibrosis evaluated by FIB-4 index and shear wave elastography in health checkup examinees.
    Yamamura S; Kawaguchi T; Nakano D; Tomiyasu Y; Yoshinaga S; Doi Y; Takahashi H; Anzai K; Eguchi Y; Torimura T; Shiba N
    Hepatol Res; 2020 Feb; 50(2):199-213. PubMed ID: 31634983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.
    Rinaldi R; De Nucci S; Donghia R; Donvito R; Cerabino N; Di Chito M; Penza A; Mongelli FP; Shahini E; Zappimbulso M; Pesole PL; Coletta S; Triggiani V; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2024 May; 16(10):. PubMed ID: 38794646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Efficacy between Pemafibrate and Omega-3-Acid Ethyl Ester in the Liver: the PORTRAIT Study.
    Sumida Y; Toyoda H; Yasuda S; Kimoto S; Sakamoto K; Nakade Y; Ito K; Osonoi T; Yoneda M
    J Atheroscler Thromb; 2024 May; ():. PubMed ID: 38777770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.
    Akhverdyan N; Wieland A; Sullivan S; Lindsay M; Swartwood S; Arndt G; Kaizer LK; Jensen T
    Metab Syndr Relat Disord; 2024 Oct; 22(8):608-618. PubMed ID: 38868900
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
    Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
    Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort.
    Oh JH; Ahn SB; Cho S; Nah EH; Yoon EL; Jun DW
    J Hepatol; 2024 Jun; ():. PubMed ID: 38879175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.
    Gurun M; Brennan P; Handjiev S; Khatib A; Leith D; Dillon JF; Byrne CJ
    PLoS One; 2024; 19(4):e0299507. PubMed ID: 38625981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study.
    Rivera-Esteban J; Jiménez-Masip A; Muñoz-Martínez S; Augustin S; Guerrero RA; Gabriel-Medina P; Ferrer-Costa R; Rodríguez-Frías F; Turu E; Marco A; Pericàs JM; On Behalf Of The Prisonafld Study Group Collaborators
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Independent Factors for Fatty Liver and Significant Hepatic Fibrosis Using B-Mode Ultrasound Imaging and Two Dimensional-Shear Wave Elastography in Health Check-up Examinees.
    Yamamura S; Kawaguchi T; Nakano D; Tomiyasu Y; Yoshinaga S; Doi Y; Takahashi H; Anzai K; Eguchi Y; Torimura T
    Kurume Med J; 2021 Dec; 66(4):225-237. PubMed ID: 34690209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of health checkup-based indices in identifying metabolic dysfunction-associated steatotic liver disease.
    Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Ng CH; Siddiqui MS; Fukao T; Shimizu M; Yamamoto M
    JGH Open; 2024 Jun; 8(6):e13110. PubMed ID: 38895100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study.
    Sano T; Amano K; Ide T; Isoda H; Honma Y; Morita Y; Yano Y; Nakamura H; Itano S; Miyajima I; Shirachi M; Kuwahara R; Ohno M; Kawaguchi T; Tsutsumi T; Nakano D; Arinaga-Hino T; Kawaguchi M; Eguchi Y; Torimura T; Takahashi H; Harada M; Kawaguchi T;
    Hepatol Res; 2024 Apr; 54(4):326-335. PubMed ID: 37975277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.